Grail's NHS-Galleri Trial Fails to Meet Primary Endpoint
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Source: PRnewswire
- Trial Result Failure: Grail's NHS-Galleri trial, which aimed to achieve a statistically significant reduction in Stage III and IV cancers, failed to meet its primary endpoint as disclosed on February 19, 2026, resulting in a staggering 50.55% drop in stock price in a single day.
- Investor Losses: Following the announcement, Grail's shares plummeted from $101.53 to $50.21, translating to a loss of $51.32 per share, indicating a severe erosion of investor confidence and substantial financial losses for shareholders.
- Insufficient Disclosure: The lawsuit alleges that Grail executives failed to disclose critical internal review results during the trial period, misleading investors about the likelihood of success and suggesting that known risks should have been transparently communicated.
- Legal Implications: The fallout from this incident has led to a lawsuit emphasizing that Grail's lack of honest communication regarding trial risks may result in investor claims for compensation, further impacting the company's reputation and future funding capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 59.450
Low
38.00
Averages
60.86
High
83.71
Current: 59.450
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Grail's NHS-Galleri Trial Fails to Meet Primary Endpoint
- Trial Result Failure: Grail's NHS-Galleri trial, which aimed to achieve a statistically significant reduction in Stage III and IV cancers, failed to meet its primary endpoint as disclosed on February 19, 2026, resulting in a staggering 50.55% drop in stock price in a single day.
- Investor Losses: Following the announcement, Grail's shares plummeted from $101.53 to $50.21, translating to a loss of $51.32 per share, indicating a severe erosion of investor confidence and substantial financial losses for shareholders.
- Insufficient Disclosure: The lawsuit alleges that Grail executives failed to disclose critical internal review results during the trial period, misleading investors about the likelihood of success and suggesting that known risks should have been transparently communicated.
- Legal Implications: The fallout from this incident has led to a lawsuit emphasizing that Grail's lack of honest communication regarding trial risks may result in investor claims for compensation, further impacting the company's reputation and future funding capabilities.
See More
Reminder of Securities Fraud Lawsuit for Grail, Inc. Investors
- Lawsuit Deadline: The Law Offices of Howard G. Smith remind investors that the deadline to file a lead plaintiff motion in the securities fraud lawsuit against Grail, Inc. (NASDAQ:GRAL) is August 4, 2026, for those who purchased shares between May 13, 2025, and February 19, 2026.
- Stock Price Plunge: Following the announcement on February 19, 2026, that the NHS-Galleri Trial did not meet its primary endpoint, Grail's stock price plummeted by 50.5% to close at $50.21 per share on February 20, 2026, significantly harming investors.
- False Statements Allegation: The lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, misleading investors regarding the company's performance.
- Investor Rights Protection: Affected investors are encouraged to contact the Law Offices of Howard G. Smith to participate in the lawsuit and understand their legal rights, ensuring they receive appropriate protection and compensation in the ongoing legal proceedings.
See More
Reminder of Securities Fraud Class Action Against GRAIL, Inc.
- Lawsuit Deadline: GRAIL, Inc. (NASDAQ: GRAL) faces a securities fraud class action lawsuit with a deadline of August 4, 2026, for investors to submit necessary documents to participate, as failure to act promptly may result in forfeiting potential recovery.
- Investor Losses: The lawsuit targets investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, alleging that the company and its executives made materially false and misleading statements regarding business operations, growth prospects, and financial stability, leading to artificially inflated stock prices and significant investor losses.
- Law Firm Credentials: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, showcasing its strong capability in investor rights protection.
- Class Action Participation: Investors wishing to serve as lead plaintiffs must file by the deadline, although participation in the lawsuit does not require being a lead plaintiff; however, those who take no action will be considered absent class members and may lose their chance for compensation.
See More
Badger Meter Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating Badger Meter, Inc. (NYSE: BMI) for potential breaches of fiduciary duty by its executives, allowing shareholders who held shares since before April 18, 2024, to seek corporate reforms and fund recovery.
- Financial Performance Under Scrutiny: A recent securities class action alleges that Badger Meter misled investors into believing its strong financial results were due to sustainable demand-driven growth, while in reality, accelerated customer orders masked weakening demand trends.
- Declining Performance Impact: Following a series of disappointing quarterly reports in 2025 and 2026, including slowing revenue growth and declining margins, Badger Meter's stock price plummeted, resulting in significant losses for investors.
- Legal Consequences Expected: Given the allegations of misleading financial data, shareholders may pursue legal action for compensation and governance reforms, which could further impact the company's market credibility and future financing capabilities.
See More
Badger Meter Shareholder Investigation Raises Concerns
- Shareholder Investigation Initiated: Grabar Law Office is investigating whether officers and directors of Badger Meter, Inc. (NYSE:BMI) breached their fiduciary duties, focusing on shareholders who purchased and held shares since April 18, 2024, which could lead to significant governance reforms for the company.
- Financial Performance Under Scrutiny: A recently filed securities fraud class action alleges that Badger Meter's financial results were materially affected by accelerated customer orders, masking weakening demand trends, which misled investors about the company's future growth prospects and could undermine shareholder confidence.
- Significant Stock Price Decline: Following a series of disappointing quarterly announcements in 2025 and 2026, Badger Meter's stock price experienced a substantial drop, reflecting market concerns over the sustainability of its financial performance and potentially exacerbating investor losses.
- Legal Recourse Available: Shareholders holding Badger Meter shares can seek corporate reforms, fund recovery, and court-approved incentive awards, indicating that investors still have legal avenues to protect their interests in the face of potential losses.
See More
Notice of Class Action Lawsuit for GRAIL Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GRAIL (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, to apply as lead plaintiffs by August 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The complaint alleges that GRAIL's defendants provided overly positive statements while concealing significant adverse facts regarding the NHS-Galleri trial, resulting in investor losses when the true information was revealed, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its expertise and successful track record in this field.
- Investor Guidance: Investors are advised to select counsel with proven success in securities litigation to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries, which could adversely affect the outcome of the lawsuit.
See More
Grail's NHS-Galleri Trial Fails to Meet Primary Endpoint
- Trial Result Failure: Grail's NHS-Galleri trial, which aimed to achieve a statistically significant reduction in Stage III and IV cancers, failed to meet its primary endpoint as disclosed on February 19, 2026, resulting in a staggering 50.55% drop in stock price in a single day.
- Investor Losses: Following the announcement, Grail's shares plummeted from $101.53 to $50.21, translating to a loss of $51.32 per share, indicating a severe erosion of investor confidence and substantial financial losses for shareholders.
- Insufficient Disclosure: The lawsuit alleges that Grail executives failed to disclose critical internal review results during the trial period, misleading investors about the likelihood of success and suggesting that known risks should have been transparently communicated.
- Legal Implications: The fallout from this incident has led to a lawsuit emphasizing that Grail's lack of honest communication regarding trial risks may result in investor claims for compensation, further impacting the company's reputation and future funding capabilities.
See More
Reminder of Securities Fraud Lawsuit for Grail, Inc. Investors
- Lawsuit Deadline: The Law Offices of Howard G. Smith remind investors that the deadline to file a lead plaintiff motion in the securities fraud lawsuit against Grail, Inc. (NASDAQ:GRAL) is August 4, 2026, for those who purchased shares between May 13, 2025, and February 19, 2026.
- Stock Price Plunge: Following the announcement on February 19, 2026, that the NHS-Galleri Trial did not meet its primary endpoint, Grail's stock price plummeted by 50.5% to close at $50.21 per share on February 20, 2026, significantly harming investors.
- False Statements Allegation: The lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, misleading investors regarding the company's performance.
- Investor Rights Protection: Affected investors are encouraged to contact the Law Offices of Howard G. Smith to participate in the lawsuit and understand their legal rights, ensuring they receive appropriate protection and compensation in the ongoing legal proceedings.
See More
Reminder of Securities Fraud Class Action Against GRAIL, Inc.
- Lawsuit Deadline: GRAIL, Inc. (NASDAQ: GRAL) faces a securities fraud class action lawsuit with a deadline of August 4, 2026, for investors to submit necessary documents to participate, as failure to act promptly may result in forfeiting potential recovery.
- Investor Losses: The lawsuit targets investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, alleging that the company and its executives made materially false and misleading statements regarding business operations, growth prospects, and financial stability, leading to artificially inflated stock prices and significant investor losses.
- Law Firm Credentials: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, showcasing its strong capability in investor rights protection.
- Class Action Participation: Investors wishing to serve as lead plaintiffs must file by the deadline, although participation in the lawsuit does not require being a lead plaintiff; however, those who take no action will be considered absent class members and may lose their chance for compensation.
See More
Badger Meter Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating Badger Meter, Inc. (NYSE: BMI) for potential breaches of fiduciary duty by its executives, allowing shareholders who held shares since before April 18, 2024, to seek corporate reforms and fund recovery.
- Financial Performance Under Scrutiny: A recent securities class action alleges that Badger Meter misled investors into believing its strong financial results were due to sustainable demand-driven growth, while in reality, accelerated customer orders masked weakening demand trends.
- Declining Performance Impact: Following a series of disappointing quarterly reports in 2025 and 2026, including slowing revenue growth and declining margins, Badger Meter's stock price plummeted, resulting in significant losses for investors.
- Legal Consequences Expected: Given the allegations of misleading financial data, shareholders may pursue legal action for compensation and governance reforms, which could further impact the company's market credibility and future financing capabilities.
See More
Badger Meter Shareholder Investigation Raises Concerns
- Shareholder Investigation Initiated: Grabar Law Office is investigating whether officers and directors of Badger Meter, Inc. (NYSE:BMI) breached their fiduciary duties, focusing on shareholders who purchased and held shares since April 18, 2024, which could lead to significant governance reforms for the company.
- Financial Performance Under Scrutiny: A recently filed securities fraud class action alleges that Badger Meter's financial results were materially affected by accelerated customer orders, masking weakening demand trends, which misled investors about the company's future growth prospects and could undermine shareholder confidence.
- Significant Stock Price Decline: Following a series of disappointing quarterly announcements in 2025 and 2026, Badger Meter's stock price experienced a substantial drop, reflecting market concerns over the sustainability of its financial performance and potentially exacerbating investor losses.
- Legal Recourse Available: Shareholders holding Badger Meter shares can seek corporate reforms, fund recovery, and court-approved incentive awards, indicating that investors still have legal avenues to protect their interests in the face of potential losses.
See More
Notice of Class Action Lawsuit for GRAIL Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GRAIL (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, to apply as lead plaintiffs by August 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The complaint alleges that GRAIL's defendants provided overly positive statements while concealing significant adverse facts regarding the NHS-Galleri trial, resulting in investor losses when the true information was revealed, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its expertise and successful track record in this field.
- Investor Guidance: Investors are advised to select counsel with proven success in securities litigation to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries, which could adversely affect the outcome of the lawsuit.
See More
